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Objective: To describe treatment patterns associated with stroke prevention in patients with atrial fibrillation in major cities of China.
Methods:  Hospital records of patients with atrial fibrillation between 2003 and 2008 were collected from 6 tertiary hospitals located in Beijing, 
Shanghai and Guangzhou of China. In each hospital, the records were a random sample from patients with a diagnosis of atrial fibrillation. 
Information on demographics, clinical characteristics and treatment patterns of anticoagulant and antiplatelet regimens were extracted by reviewing 
the records. A descriptive analysis was performed.
Results:  A total of 2862 patients were reviewed with 55% males and average age of 72 years old (49% 75+ years old). Among all patients, 15% 
were valvular atrial fibrillation, 78% were non-valvular atrial fibrillation, and the remaining 8% as unidentified. About 53% of patients were with 
CHADS2 score of 2 or above. With regard to treatment patterns associated with stroke prevention, about 18% were with no anticoagulation or 
antiplatelet treatment. One-drug only regimen accounted for 42% (including 20% aspirin, 13% warfarin, 5% clopidogrel and 3% low weight heparin), 
two-drug regimen accounted for 29% (including 12 % warfarin and low weight heparin, 7% aspiring and clopidogrel, 4% warfarin and aspirin and 3% 
aspiring and low weight heparin), three-drug regimen for 9%, and the remaining four- and five-drug regimens for 2%. There is no clear relationship 
between CHADS2 score and proportion of patients treated with anticoagulants and antiplatelets.
Conclusion: The treatment regimens for stroke prevention among atrial fibrillation patients vary substantially in China. It appears the therapy given 
was not associated with stroke risk. 
